Mon.Jan 13, 2025

article thumbnail

J&J Bolsters Its Prospects in Brain Health With $14B Buyout of Intra-Cellular Therapies

MedCity News

Johnson & Johnsons agreement to acquire Intra-Cellular Therapies brings Caplyta, which is projected to become a blockbuster seller across several neurological indications. In other M&A news, GSK and Eli Lilly each struck deals to fill their cancer drug pipelines. The post J&J Bolsters Its Prospects in Brain Health With $14B Buyout of Intra-Cellular Therapies appeared first on MedCity News.

article thumbnail

Biogen offers to buy out wilting Sage for $442 million

pharmaphorum

Biogen has offered to buy all the shares in Sage Therapeutics that it doesn't already own, taking control of their novel antidepressant Zurzuvae.The $7.22-per-share deal for 89.8% of Sage is a 30% premium on the company's share price on Friday and is estimated by Reuters to be worth around $442 million. Biogen has a longstanding alliance in place with Sage and co-markets Zurzuvae (zuranolone), which is FDA-approved for post-partum depression (PPD).

FDA 105
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

GSK acquisition to advance potential best-in-class GI tumour treatment

European Pharmaceutical Review

GSK has agreed to acquire the biopharmaceutical firm IDRx Inc, a company focused on development of precision therapies for gastrointestinal stromal tumours (GIST). The deal is valued up to $1.15 billion, which includes an upfront payment of $1 billion. IDRx Inc could receive a further $150 million, subject to achievement of future regulatory approvals.

article thumbnail

FDA ‘stuck to its corner’ with AI draft guidance, leaving plenty of questions unanswered

PharmaVoice

The first draft guidance provides an initial framework for how the agency will assess AI models in drug development, but the industry is still looking for more.

FDA 147
article thumbnail

State of AI in Sales & Marketing 2025

AI adoption is reshaping sales and marketing. But is it delivering real results? We surveyed 1,000+ GTM professionals to find out. The data is clear: AI users report 47% higher productivity and an average of 12 hours saved per week. But leaders say mainstream AI tools still fall short on accuracy and business impact. Download the full report today to see how AI is being used — and where go-to-market professionals think there are gaps and opportunities.

article thumbnail

AI set to revolutionise pharmaceutical R&D says GlobalData

PharmaTimes

Survey finds AI to enhance productivity and cut costs in the next 12 months

More Trending

article thumbnail

Gilead and LEO Pharma partner to develop oral STAT6 program

PharmaTimes

Companies aim to provide new treatments for inflammatory conditions

Pharma 113
article thumbnail

JP Morgan 2025: NVIDIA partners with IQVIA, Illumina and Mayo Clinic

Pharmaceutical Technology

NVIDIA starts 2025 by announcing a trio of partnerships and a research collaboration to boost healthcare sector presence.

article thumbnail

The Role of AI in Patient Care

LEVO Health

Artificial intelligence (AI) is rapidly revolutionizing the healthcare industry, reshaping the patient experience in the process. By leveraging AI in patient care, healthcare providers can improve patient outcomes, enhance efficiency, and reduce costs all while providing a more personalized and seamless patient experience. The AI healthcare market is projected to reach a value of $188 billion by 2030.

article thumbnail

GSK confirms plan to buy cancer firm IDRx for $1bn

pharmaphorum

GSK confirms that it has agreed to buy US biotech IDRx and its KIT inhibitor for rare gastrointestinal tumours for $1bn upfront.

103
103
article thumbnail

The Intersection of AI and Sales: Personalization Without Compromise

Speaker: Jesse Hunter and Brynn Chadwick

Today’s buyers expect more than generic outreach–they want relevant, personalized interactions that address their specific needs. For sales teams managing hundreds or thousands of prospects, however, delivering this level of personalization without automation is nearly impossible. The key is integrating AI in a way that enhances customer engagement rather than making it feel robotic.

article thumbnail

Dealing with Challenging APIs

PharmaTech

Pharmaceutical Technology chats about the increasing prevalence of challenging APIs in the development pipeline and the hurdles facing formulators and manufacturers as a result of this trend with Jens Schmidt from Lonza.

article thumbnail

Nine-month-old obesity player Metsera files an IPO

pharmaphorum

Metsera is leaving no fundraising stone unturned as it races to grab a slice of the fast-growing market for obesity drugs, cueing up an IPO.

article thumbnail

Telix Enters Agreement with ImaginAb to Purchase Next-Gen Therapeutic Candidates

PharmaTech

The transaction adds a pipeline of early-stage drug candidates against high-value targets to Telixs portfolio, along with other novel targets currently in the discovery stage.

59
article thumbnail

Regeneron, Illumina join $320m Truveta investment

pharmaphorum

Regeneron and Illumina have joined a major investment in health data specialist Truveta that will support the creation of a major new genome project.

96
article thumbnail

The GTM Intelligence Era: ZoomInfo 2025 Customer Impact Report

ZoomInfo customers aren’t just selling — they’re winning. Revenue teams using our Go-To-Market Intelligence platform grew pipeline by 32%, increased deal sizes by 40%, and booked 55% more meetings. Download this report to see what 11,000+ customers say about our Go-To-Market Intelligence platform and how it impacts their bottom line. The data speaks for itself!

article thumbnail

Eli Lilly targets Scorpion Therapeutics to expand reach in oncology

Pharmaceutical Technology

After selling its PI3K program to Eli Lilly, Scorpion will spinout out a different entity, which will be owned by the biotechs current shareholders.

59
article thumbnail

J&J agrees $14.6bn takeover of CNS biotech Intra-Cellular

pharmaphorum

Johnson & Johnson has agreed to take over Intra-Cellular Therapies and its potential depression blockbuster Caplyta in a deal worth up to $14.6bn.

75
article thumbnail

Pfizer pitches pipeline priorities in oncology and obesity at JP Morgan 2025

Pharmaceutical Technology

CEO Albert Bourla expressed modest optimism for Pfizers 2025 revenues at JPM 2025, supported by plans to prioritize R&D in oncology and obesity.

59
article thumbnail

Lilly nets Scorpion cancer drug in $2.5bn licensing deal

pharmaphorum

Eli Lilly has unveiled a $2.5 billion deal to acquire rights to a breast cancer therapy being developed by Scorpion Therapeutics.

59
article thumbnail

AI in Marketing & Sales: Today’s Tools, Tomorrow’s Potential

Speaker: Kevin Burke

AI is reshaping marketing and sales, empowering professionals to work smarter, faster, and more effectively. This webinar will provide a practical introduction to AI, focusing on its current applications, transformative potential, and strategies for successful implementation in your organization. Using real-world examples and actionable insights, we’ll examine how businesses are leveraging AI to increase efficiency, enhance personalization, and drive measurable results.

article thumbnail

BioDuro Opens Solid-Phase Peptide Synthesis Scale-Up Facility in Shanghai

PharmaTech

This is the latest facility launch for BioDuro, following a kilogram laboratory and compound management center, both on the same site, in October 2024.

article thumbnail

Biogen proposes acquisition of partner Sage Therapeutics

Pharmaceutical Technology

The proposed deal comes soon after Sage implemented a restructuring plan to focus on Zurzuvaes launch in postpartum depression.

59
article thumbnail

J&J Inks $14.6 Billion Intra-Cellular Therapies Deal

Pharmaceutical Commerce

The acquisition features Caplyta as part of its neuroscience portfolio, which is considered the only FDA-approved treatment for bipolar I and II depression as a monotherapy and adjunctive treatment.

FDA 59
article thumbnail

Gilead and LEO Pharma link on programmes for inflammatory conditions

Pharmaceutical Technology

Gilead and LEO Pharma have entered into a strategic collaboration to expedite the latters STAT6 programmes.

Pharma 59
article thumbnail

5 Ways You Can Win Faster with Gen AI in Sales

Incorporating generative AI (gen AI) into your sales process can speed up your wins through improved efficiency, personalized customer interactions, and better informed decision- making. Gen AI is a game changer for busy salespeople and can reduce time-consuming tasks, such as customer research, note-taking, and writing emails, and provide insightful data analysis and recommendations.

article thumbnail

Pharma Pulse 1/13/25: Additional Security Measures for J.P. Morgan Healthcare Conference, Health Plans Under Pressure & more

Pharmaceutical Commerce

The latest news for pharma industry insiders.

Pharma 59
article thumbnail

JP Morgan 2025: GSK acquires IDRx in $1.15bn deal 

Pharmaceutical Technology

IDRxs lead candidate IDRX-42 is being investigated in a Phase I/IIb trial in patients with advanced gastrointestinal stromal tumours.

Leads 59
article thumbnail

Making Sample Ordering Simpler for HCPs

Pharmaceutical Commerce

In the second part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Mark Jara, founder and CTO, RxS, explains the value of an online portal that offers logistics flexibility.

Pharma 59
article thumbnail

Johnson & Johnson in talks to acquire Intra-Cellular Therapies

Pharmaceutical Technology

Johnson & Johnson (J&J) is in discussions to acquire Intra-Cellular Therapies in the biggest biotech transaction in more than a year.

59
article thumbnail

AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

article thumbnail

Medicare Drug Pricing Reform Brings Financial Relief to Patients

Pharmacy Times

The new Medicare cap limits out-of-pocket drug costs to $2000 annually.

article thumbnail

The promising future of regenerative medicine

Pharmaceutical Technology

Regenerative medicine is an exciting field with a promising future, capable of tackling inherent challenges seen with current therapies.

article thumbnail

Gilead and LEO Pharma partner to develop oral STAT6 program

PharmaTimes

Companies aim to provide new treatments for inflammatory conditions

Pharma 52